Clinical Trial

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-22; most recent amendment 2026-01-14.
Status change: Not Yet Recruiting → Recruiting 2024-10-14
Trial Details
NCT Number NCT06194656
Lead Sponsor Shanghai Institute Of Biological Products
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 81 participants
Start Date 2024-09-27
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-16